# US 2010/0136062 A1 · Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136062 A1
- Document ID: US20100136062A1
- Status: Published application
- Kind: A1
- Application number: 12/443,837
- Filed: 2007-10-01
- Published: 2010-06-03
- Earliest claimed: 2006-10-03
- Assignees: Centro de Ingenieria Genetica y Biotecnologia
- Inventors: Jose Ignacio Fernandez Montequin; Luis Saturnino Herrera Martinez; Jorge Amador Berlanga Acosta; Diana Garcia Del Barco Herrera; Danay Cibrian Vera; Gerardo Enrique Guillen Nieto; Raimundo Ubieta Gomez; Sonia Gonzalez Blanco; Vivian Maria Saez Martinez
- Web page: https://patentgrep.com/patent/US20100136062A1

## CPC

- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/485: Epidermal growth factor [EGF], i.e. urogastrone
- Y10S 930/12: Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.

## Claims

### Claim 1

The use of Epidermal Growth Factor (EGF) to prepare a pharmaceutical composition administered by infiltration in the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of the peripheral nerves affected by diabetic neuropathy.

### Claim 2 (depends on 1)

The use of Epidermal Growth Factor (EGF) according to claim 1 where diabetic neuropathy refers to sensitive-motor, painful neuropathy, and ischemic neuritis.

### Claim 3 (depends on 1)

The use of EGF according to claim 1, wherein sensitive-motor, painful neuropathy, or ischemic neuritis affect the lower limbs.

### Claim 4 (depends on 1)

The use of EGF according to claim 1, wherein said growth factor is the human, recombinant EGF.

### Claim 5 (depends on 1)

The use of EGF according to claim 1, wherein said EGF is encapsulated in microspheres.

### Claim 6 (depends on 1)

The use of EGF according to claim 1, wherein said EGF containing pharmaceutical composition is liquid or lyophilized to be reconstituted before its use.

### Claim 7 (depends on 6)

The use of EGF according to claim 6, wherein said EGF containing pharmaceutical composition is an aqueous composition, optionally buffered, or a lyophilized composition to be reconstituted with water, or with an aqueous buffer solution.

### Claim 8 (depends on 1)

The use of EGF according to claim 1 wherein said pharmaceutical composition, contains from 10 to 1000 micrograms of EGF/milliliter.

### Claim 9 (depends on 1)

The use of EGF according to claim 1, wherein said EGF containing pharmaceutical composition, additionally contains from 10 micrograms to 500 milligrams of at least one local anesthetic or analgesic selected among the group of lidocaine, bupivacaine or novocaine.

### Claim 10 (depends on 9)

The use of EGF according to claim 9, wherein the local anesthetic is 2% lidocaine.

### Claim 11

A pharmaceutical composition for the treatment of sensitive-motor, painful diabetic neuropathy; ischemic neuritis in the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of the peripheral nerves, which contains EGF in combination with a local anesthetic or analgesic.

### Claim 12 (depends on 11)

A pharmaceutical composition according to claim 11 wherein EGF is encapsulated in microspheres.

### Claim 13 (depends on 11)

A pharmaceutical composition according to claim 11 wherein the anesthetic is a local anesthetic selected from the group of lidocaine, bupivacaine or novocaine.

### Claim 14 (depends on 11)

A pharmaceutical composition according to claim 11 wherein EGF is in the range of 10 to 1000 micrograms/milliliter.

### Claim 15 (depends on 11)

The use of the pharmaceutical composition of claim 11 in the morphofunctional restoration of peripheral nerves in sensitive-motor, painful diabetic neuropathy and/or ischemic neuritis.

### Claim 16 (depends on 15)

The use of the pharmaceutical composition according to claim 15, to treat any sort of motor fiber damage associated with diabetic neuropathy.
